PressAdda
Russian scientists have announced a historic achievement in the fight against cancer. According to the Federal Medical and Biological Agency (FMBA) of Russia, the Entromix cancer vaccine is now ready for clinical use. Citing FMBA chief Veronika Skvortsova, Russian media outlet Sputnik reported that the mRNA-based vaccine has demonstrated remarkable success in preclinical trials.
Safe for Use
– The vaccine has shown effectiveness in reducing tumor size and slowing their growth.
– Trials confirmed a 60–80% reduction in tumor progression.
– It has been found safe for repeated use.
– The vaccine will be customized for each patient based on their individual RNA profile.
Awaiting Approval
– The research spanned several years, with the last three dedicated to preclinical studies.
– FMBA chief stated, “The vaccine is ready for use. We are awaiting official approval.”
– Studies indicate an increase in survival rates due to the vaccine.
– FMBA submitted an application for approval to the Ministry of Health earlier this summer.
Initial Application and Future Plans
– The first version of the vaccine will be used to treat colorectal cancer.
– Promising progress has also been made in developing vaccines for glioblastoma (a type of brain cancer) and melanoma (skin cancer), which are currently in advanced stages of development.This announcement marks a new ray of hope in the field of medical science.
